Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

Inclusion Criteria:

Subjects with Multiple Myeloma (MM) and renal function fitting one of three categories:

Severe renal impairment: estimated creatinine clearance (CrCl) <30 ml/min, but not requiring dialysis
End-stage renal disease: requiring hemodialysis
Normal renal function: estimated CrCl ≥90 ml/min
Documented evidence of symptomatic MM, either newly diagnosed or relapsed/refractory
Prior Lenalidomide exposure is permitted only if the subject did not discontinue Lenalidomide due to a Grade ≥3 related Adverse Event (AE)

Exclusion Criteria:

Monoclonal Gammopathy of Undetermined Significance (MGUS), Waldenstrom's macroglobulinemia, or smoldering myeloma
Active plasma cell leukemia
All adverse events of any prior chemotherapy, surgery, or radiotherapy not resolved
POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
Acute renal failure